Comparative Pharmacology
Head-to-head clinical analysis: MYMETHAZINE FORTIS versus PROMETHAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYMETHAZINE FORTIS versus PROMETHAZINE HYDROCHLORIDE.
MYMETHAZINE FORTIS vs PROMETHAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mymethazine fortis is a phenothiazine derivative that exerts antipsychotic and antiemetic effects primarily by blocking postsynaptic dopamine D2 receptors in the mesolimbic system, as well as possessing anticholinergic, antihistaminergic, and alpha-adrenergic antagonistic properties.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, blocking the effects of histamine at H1 receptors. It also has anticholinergic, antiemetic, sedative, and antidopaminergic properties.
50 mg orally every 6 hours as needed for nausea and vomiting.
25-50 mg intramuscular or intravenous injection every 4-6 hours as needed; also 12.5-25 mg orally every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life is 15-20 hours; in renal impairment (CrCl <30 mL/min), may extend to 30-40 hours, requiring dose adjustment.
Terminal elimination half-life is 10-19 hours in adults; prolonged in hepatic impairment (up to 30+ hours) and in elderly.
Primarily renal (70-80% as unchanged drug and metabolites, with about 30% as unchanged); fecal (10-15%) via biliary elimination.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <1% of unchanged drug; biliary/fecal excretion of metabolites ~70-80%.
Category C
Category A/B
Antihistamine/Decongestant Combination
Antihistamine / Antiemetic